Eli Lilly and Company’s recently released topline results from its pivotal Phase III trial on donanemab in Alzheimer’s disease showed a significant clinical benefit, bolstering the company’s position that the Centers for Medicare and Medicaid Services should allow unrestricted Medicare coverage once the drug is approved.
Early results from Lilly’s TRAILBLAZER-ALZ 2 trial, released 3 May, show a 35% slowing in clinical cognitive decline for early Alzheimer’s patients